Proceedings of the National Academy of Sciences
June 16, 2026
Adam R Pines, Xue Zhang, John Kochalka et al.
Psychedelic drugs are poised to become mainstream treatments, yet we lack a circuit-level account of how they reshape brain activity. Emerging evidence suggests that multiple psychedelic compounds modulate activity in the brain's default mode network (DMN), often interpreted as either increased or decreased bottom-up hierarchical processing. Most imaging studies, however, quantify activity as...
Journal of Psychoactive Drugs
October 11, 2022
Jeremy Weleff, Teddy J. Akiki, Brian S. Barnett
11 citations
Following a decades long period of investigational dormancy, there is renewed interest in employing psychedelics as psychiatric treatments. The academic journals, institutions, and countries that have helped sustain clinical psychedelic research and the evolution of the literature on clinical studies of psychedelics have only recently begun to be investigated. To expand upon this work, we...
Journal of Affective Disorders
July 1, 2022
Thomas D Hull, Matteo Malgaroli, Adam Gazzaley et al.
59 citations
BACKGROUND At-home Ketamine-assisted therapy (KAT) with psychosocial support and remote monitoring through telehealth platforms addresses access barriers, including the COVID-19 pandemic. Large-scale evaluation of this approach is needed for questions regarding safety and effectiveness for depression and anxiety. METHODS In this prospective study, a large outpatient sample received KAT over...
Figshare
2021
Jeremy Weleff, Teddy J. Akiki, Brian S. Barnett
preprint
Dataset for a bibliometric analysis of journal articles reporting findings from clinical studies of the psychedelics 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT), ayahuasca, dimethyltryptamine (DMT), ibogaine, lysergic acid diethylamide (LSD), mescaline, MDMA, and psilocybin published from 1965-2018.This data accompanies our article:Bibliometric Analysis of Academic Journal Articles Reporting...
The Annual Review of Pharmacology and Toxicology
September 14, 2018
Chadi G. Abdallah, Lynnette A. Averill, Teddy J. Akiki et al.
New approaches to the neurobiology of posttraumatic stress disorder (PTSD) are needed to address the reported crisis in PTSD drug development. These new approaches may require the field to move beyond a narrow fear-based perspective, as fear-based medications have not yet demonstrated compelling efficacy. Antidepressants, particularly recent rapid-acting antidepressants, exert complex effects...
Chronic Stress
2018
Chadi G. Abdallah, Arpan Dutta, Christopher L. Averill et al.
Identifying the neural correlates of ketamine treatment may facilitate and expedite the development of novel, robust, and safe rapid-acting antidepressants. Prefrontal cortex (PFC) global brain connectivity with global signal regression (GBCr) was recently identified as a putative biomarker of major depressive disorder (MDD). Accumulating evidence have repeatedly shown reduced PFC GBCr in MDD,...